Pharma CBD Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 127 studies associated with Pharma CBD.
Here is a small sampling of Pharma CBD studies by title:
- Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, oxycodone or cannabis/oxycodone combination-the SPIRAL study
- Effect of Cannabidiol Oil on Post-ureteroscopy Pain for Urinary Calculi: A Randomized, Double-blind, Placebo-controlled Trial
- Cannabidiol Treatment for Neurological, Cognitive, and Psychiatric Symptoms in Sturge-Weber Syndrome
- Climbing the Evidence Pyramid: Dosing Considerations for Medical Cannabis in the Management of Chronic Pain
- Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
Components of the Pharma CBD Research Dashboard
- Top medical conditions associated with Pharma CBD
- Proven effects in clinical trials for Pharma CBD
- Receptors associated with Pharma CBD
- Individual study details for Pharma CBD
Ready to become a subscriber? Go to our PRICING page.
Page Quick Links
Select New Cannabinoid
Overview - Pharma CBD
Description of Pharma CBD
Pharmacologically produced products containing CBD correspond to a cannabis chemotype III. They represent a class of drugs that are produced and standardized from either man-made or plant-based materials.
The Federal Drug Administration (FDR) approved (June 25, 2018) a pharmaceutical version of CBD (Epidiolex) for marketing in the treatment of a couple of rare pediatric seizure disorders (Lennox-Gastaut syndrome and Dravet sundrome).
Other Names:
Pharmaceutical CBDEpidiolex, Cannabidiol, (-)-Cannabidiol, (-)-trans-Cannabidiol
IUPAC Name: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Molecular Formula: C21H30O2
Source– PubChem
Pharma CBD Properties and Effects
Only Members can view Properties and Effects information. See DEMO page.
Pharma CBD Receptor Binding
Only Members can view Receptor Binding information. See DEMO page.
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
